Physician profile
Michael E Kasabian
NPI 1275527293
$10,329.19
in general payments reported to CMS, 2019-2025
50 companies · $1,204 in 2025
The $1,204 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,374 · 2020: $1,679 · 2021: $1,606 · 2022: $1,004 · 2023: $1,052 · 2024: $1,410 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,466 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,465.65 |
| Education | $200.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,090.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $998.85 | 2019-2025 | Trelegy Ellipta, Shingrix, Boostrix |
| Astrazeneca Pharmaceuticals LP | $897.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $719.95 | 2019-2025 | |
| Amgen INC. | $652.14 | 2019-2025 | Uplizna, Evenity, Prolia |
| Lilly USA, LLC | $584.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sunovion Pharmaceuticals INC. | $500.18 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $492.13 | 2019-2025 | Spravato, Xarelto |
| Abbvie INC. | $459.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.77 | 2019-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $333.74 | 2023-2025 | Gemtesa |
| Amarin Pharma, INC. | $302.73 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $297.79 | 2019-2021 | |
| Astellas Pharma US INC | $293.58 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $277.55 | 2019-2025 | Trintellix |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kasabian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.